ICRH researcher joins call in Lancet Oncology to decrease price of new essential cancer medicines

ICRH's Dr. Katrina Perehudoff joined health researchers and advocates issuing a call in Lancet Oncology for governments & stakeholders to act now to decrease the price of new essential cancer medicines.

This call comes after WHO added 10 new cancer therapies to its 21st Model List of Essential Medicines in July 2019.  Labeling medicines as essential, means that they have proven their utility and should be available and affordable to all,  moving towards increasing access to cancer medicines in low-income and middle-income countries. Dr. Perehudoff and her co-authors urge governments to expand access to these new medicines with strategies used in the past to scale-up access to HIV and Hepatitis C therapies. 

You can read the full article here.